STOLBERG, Germany, November 7, 2014 /PRNewswire/ —
The individual risk of stroke, kidney failure and heart attack is the decisive factor over whether to start treatment for high blood pressure or increased cholesterol. The risk can be identified at any early stage by measuring the pulse wave velocity (PWV).
IEM – based in Stolberg/Germany – will present the clinically validated PWV system, "Measuring blood pressure and PWV in one", at Medica 2014.
Scientific data shows that the PWV is an independent predictor for cardiovascular events and is significantly superior to simply evaluating traditional risk factors, e.g. increased blood pressure or cholesterol or risk assessment based on the Framingham risk score.
The basic principle of the innovative PWV test method is the combination of blood pressure measurement and pulse wave analysis. PWV is considered the gold standard in arterial stiffness evaluation. It is well known that the stiffer the arteries, the greater the risk of cardiovascular diseases.
The benefit to patients and medical practitioners is the differentiation between vascular health and cardiovascular risk. The advantage is that by measuring the upper-arm blood pressure and PWV in one, a patient can be classified into "low risk" or "very high risk". This provides to the doctor a quick and solid basis for taking a decision on treatment.
The first comprehensive validated test system with the upper-arm cuff is the Mobil-O-Graph®, which was validated against invasive catheterisation under very strict conditions.
Visit IEM GmbH at Medica from 12th – 15th November 2014 in Hall 9, Stand C68. Have your blood pressure pulse wave analysis performed.
Contact address for complete article and editing